Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Blair William & Co. IL

Blair William & Co. IL cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.3% during the fourth quarter, HoldingsChannel reports. The firm owned 11,962 shares of the biopharmaceutical company’s stock after selling 1,372 shares during the period. Blair William & Co. IL’s holdings in Alnylam Pharmaceuticals were worth $2,815,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company’s stock worth $2,996,296,000 after buying an additional 98,303 shares during the last quarter. Regeneron Pharmaceuticals Inc. purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $1,045,822,000. Geode Capital Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 3.2% in the third quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock valued at $589,209,000 after purchasing an additional 66,928 shares during the period. American Century Companies Inc. raised its stake in shares of Alnylam Pharmaceuticals by 0.7% during the fourth quarter. American Century Companies Inc. now owns 1,604,024 shares of the biopharmaceutical company’s stock worth $377,443,000 after purchasing an additional 11,291 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 5.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 513,962 shares of the biopharmaceutical company’s stock worth $120,940,000 after purchasing an additional 26,614 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ALNY. Morgan Stanley upped their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. HC Wainwright raised their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research report on Monday, February 24th. Chardan Capital reaffirmed a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Sanford C. Bernstein cut their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Finally, Redburn Atlantic initiated coverage on Alnylam Pharmaceuticals in a research note on Monday. They issued a “buy” rating and a $353.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $316.25.

Insider Activity at Alnylam Pharmaceuticals

In other news, CFO Jeffrey V. Poulton sold 967 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $246,749.39. Following the transaction, the chief financial officer now directly owns 32,786 shares in the company, valued at $8,366,003.62. This represents a 2.86 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Yvonne Greenstreet sold 1,213 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the sale, the chief executive officer now owns 81,526 shares of the company’s stock, valued at approximately $20,802,989.42. The trade was a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 71,234 shares of company stock valued at $19,958,097. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $270.02 on Tuesday. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The business has a fifty day moving average of $260.34 and a 200-day moving average of $260.58. The stock has a market cap of $35.13 billion, a price-to-earnings ratio of -124.43 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.